Skye Accounts Payable vs Non Current Assets Total Analysis
| SKYE Stock | USD 4.41 0.13 3.04% |
Skye Bioscience, financial indicator trend analysis is much more than just breaking down Skye Bioscience, Common prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Skye Bioscience, Common is a good investment. Please check the relationship between Skye Bioscience, Accounts Payable and its Non Current Assets Total accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Skye Bioscience, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
Accounts Payable vs Non Current Assets Total
Accounts Payable vs Non Current Assets Total Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Skye Bioscience, Common Accounts Payable account and Non Current Assets Total. At this time, the significance of the direction appears to have strong relationship.
The correlation between Skye Bioscience,'s Accounts Payable and Non Current Assets Total is 0.73. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Non Current Assets Total in the same time period over historical financial statements of Skye Bioscience, Common, assuming nothing else is changed. The correlation between historical values of Skye Bioscience,'s Accounts Payable and Non Current Assets Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Skye Bioscience, Common are associated (or correlated) with its Non Current Assets Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Current Assets Total has no effect on the direction of Accounts Payable i.e., Skye Bioscience,'s Accounts Payable and Non Current Assets Total go up and down completely randomly.
Correlation Coefficient | 0.73 |
| Relationship Direction | Positive |
| Relationship Strength | Significant |
Accounts Payable
An accounting item on the balance sheet that represents Skye Bioscience, obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Skye Bioscience, Common are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Non Current Assets Total
The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.Most indicators from Skye Bioscience,'s fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Skye Bioscience, Common current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Skye Bioscience, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. At present, Skye Bioscience,'s Sales General And Administrative To Revenue is projected to increase slightly based on the last few years of reporting.
| 2021 | 2022 | 2023 | 2024 (projected) | Tax Provision | 2.1K | 6.7K | 3.6K | 3.0K | Income Tax Expense | 2.1K | 6.7K | 3.6K | 2.8K |
Skye Bioscience, fundamental ratios Correlations
Click cells to compare fundamentals
Skye Bioscience, Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Skye Bioscience, fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Other Current Liab | 410.6K | 341.8K | 954.9K | 7.6M | 8.3M | 4.7M | |
| Total Current Liabilities | 970.8K | 787.2K | 3.9M | 12.1M | 13.9M | 14.6M | |
| Net Tangible Assets | (15.6M) | 548.1K | 450.8K | 5.9M | 6.7M | 7.1M | |
| Retained Earnings | (32.2M) | (38.7M) | (47.3M) | (66.7M) | (104.4M) | (99.2M) | |
| Accounts Payable | 129.8K | 381.4K | 900.0K | 1.8M | 1.2M | 653.5K | |
| Other Current Assets | 12.1K | 195.0K | 629.1K | 412.0K | 11.0M | 11.5M | |
| Total Current Assets | 2.0M | 2.7M | 9.6M | 8.9M | 11.7M | 12.2M | |
| Common Stock | 182.9K | 288.1K | 476.1K | 913.5K | 12.3K | 11.7K | |
| Property Plant Equipment | 3.4K | 2.0K | 7.3K | 234.7K | 269.9K | 283.4K | |
| Total Assets | 2.0M | 2.7M | 9.9M | 9.1M | 11.9M | 6.0M | |
| Total Stockholder Equity | 548.1K | 450.8K | 5.9M | (3.0M) | (2.1M) | (2.2M) | |
| Cash | 1.8M | 2.5M | 9.0M | 1.2M | 1.3M | 1.2M | |
| Non Current Assets Total | 2.0K | 7.3K | 243.0K | 167.4K | 289.6K | 304.0K | |
| Common Stock Shares Outstanding | 182.9M | 1.0M | 1.7M | 493.7M | 7.0M | 6.7M | |
| Non Current Liabilities Total | 477.9K | 1.4M | 78.7K | 1.7M | 171.2K | 162.7K | |
| Total Liab | 1.4M | 2.2M | 4.0M | 12.1M | 14.1M | 8.3M | |
| Net Invested Capital | 935.1K | 1.9M | 7.8M | (1.2M) | 2.2M | 2.4M | |
| Net Working Capital | 1.0M | 1.9M | 5.7M | (3.2M) | (2.3M) | (2.4M) | |
| Capital Stock | 182.9K | 288.1K | 476.1K | 913.5K | 12.3K | 11.7K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Skye Bioscience, Common is a strong investment it is important to analyze Skye Bioscience,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Skye Bioscience,'s future performance. For an informed investment choice regarding Skye Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Skye Bioscience, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Skye Bioscience,. If investors know Skye will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Skye Bioscience, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.60) | Return On Assets (0.30) | Return On Equity (0.55) |
The market value of Skye Bioscience, Common is measured differently than its book value, which is the value of Skye that is recorded on the company's balance sheet. Investors also form their own opinion of Skye Bioscience,'s value that differs from its market value or its book value, called intrinsic value, which is Skye Bioscience,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Skye Bioscience,'s market value can be influenced by many factors that don't directly affect Skye Bioscience,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Skye Bioscience,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Skye Bioscience, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Skye Bioscience,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.